| Assay ID | Title | Year | Journal | Article |
|---|
| AID1860388 | Inhibition of recombinant human PLK4 incubated for 60 mins by Lanthascreen Eu kinase binding assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860521 | Selectivity index, ratio of IC50 for inhibition of Aurora B (unknown origin) to IC50 for inhibition of PLK4 (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860518 | Inhibition of Aurora C (unknown origin) by Z'-LYTE kinase assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860393 | Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860456 | Antiproliferative activity against TRIM37 amplified human BT-474 cells assessed as inhibition of cell proliferation at 150 nM incubated for 4 to 8 days by passsaging based LUNA-II automated cell counter | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860515 | Inhibition of PLK4 (unknown origin) by Lanthascreen Eu Kinase binding assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860454 | Antiproliferative activity against TRIM37 non-amplified human K562 cells assessed as inhibition of cell proliferation at 150 nM incubated for 4 to 8 days by passsaging based LUNA-II automated cell counter | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860391 | Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860453 | Antiproliferative activity against TRIM37 non-amplified human MDA-MB-231 cells assessed as inhibition of cell proliferation at 150 nM incubated for 4 to 8 days by passsaging based LUNA-II automated cell counter | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860455 | Antiproliferative activity against TRIM37 amplified human MCF7 cells assessed as inhibition of cell proliferation at 150 nM incubated for 4 to 8 days by passsaging based LUNA-II automated cell counter | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860517 | Inhibition of Aurora B (unknown origin) by Z'-LYTE kinase assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860392 | Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition incubated for 5 days by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860383 | Antiproliferative activity against human MCF7 cells assessed as reduction in colony formation incubated for 14 days by cresyl-violet staining based assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860522 | Selectivity index, ratio of IC50 for inhibition of Aurora C (unknown origin) to IC50 for inhibition of PLK4 (unknown origin) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| AID1860516 | Inhibition of Aurora A (unknown origin) by Z'-LYTE kinase assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |